Search

PTC Therapeutics Inc

Lezárt

SzektorEgészségügy

65.31 -5.24

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

65.31

Maximum

69.33

Fő mutatók

By Trading Economics

Bevétel

-135M

-52M

Értékesítés

-2.7M

358M

P/E

Szektor átlag

7.597

51.78

Egy részvényre jutó nyereség

0.61

Profit margin

-14.447

Munkavállalók

991

EBITDA

-140M

22M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+44.99% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-11M

5.1B

Előző nyitás

70.55

Előző zárás

65.31

PTC Therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. nov. 5. 21:04 UTC

Correlated Moves

PTC Therapeutics shares fell amid a broader decline in the biotechnology sector, as the SPDR S&P Biotech ETF (XBI) experiences significant losses.

2026. nov. 4. 20:26 UTC

Correlated Moves

PTC Therapeutics shares are modestly higher, supported by advances in the iShares Biotechnology ETF following positive news on Moderna's mRNA vaccine candidate.

2026. nov. 3. 21:02 UTC

Social Media
News

PTC Therapeutics' Board approved a $500 million share repurchase program, reflecting confidence in growth prospects and generating positive sentiment around the stock.

2026. nov. 2. 21:09 UTC

News

Citigroup reaffirms Buy rating on PTC Therapeutics and raises price target to $109, as the company prepares for upcoming investor conferences.

2026. okt. 30. 20:04 UTC

Social Media
News

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million and a basic EPS of -$0.62, overshadowing positive analyst ratings and price target increases.

2026. okt. 29. 20:13 UTC

News

PTC Therapeutics reported a Q3 2026 net loss of $51.7 million, missing EPS estimates despite revenue of $358 million and raising full-year guidance to $1.29 to $1.32 billion.

2026. okt. 28. 19:36 UTC

PTC Therapeutics, Inc. is trading higher, having reached a peak cumulative return, consistent with three consecutive daily advances.

2026. okt. 27. 20:07 UTC

Correlated Moves

PTC Therapeutics is trading higher, supported by positive momentum in the biotechnology sector and gains in the SPDR S&P Biotech ETF.

2026. okt. 23. 20:01 UTC

PTC Therapeutics Inc shares are declining, reversing the recent trend of higher daily closes since Thursday's close.

2026. okt. 20. 20:08 UTC

Correlated Moves

PTC Therapeutics Inc is advancing, reflecting a broader positive trend in biotechnology stocks as the SPDR S&P Biotech ETF (XBI) also moves higher.

2026. okt. 19. 20:01 UTC

PTC Therapeutics Inc shares are advancing despite a broader market downturn, continuing the upward momentum observed in recent sessions.

2026. okt. 15. 20:02 UTC

News
Correlated Moves

UBS analyst Joon Lee raised the price target on PTC Therapeutics Inc to $90.00 from $80.00 while maintaining a Buy rating.

2026. okt. 13. 20:01 UTC

PTC Therapeutics Inc shares fell sharply, continuing a decline near the low end of their one-month range and below the 20-day moving average.

2026. okt. 9. 20:01 UTC

Correlated Moves

PTC Therapeutics Inc shares are advancing, recovering from an earlier dip, as the iShares Biotechnology ETF also rises, supported by strong gains in key holdings.

2026. okt. 8. 20:07 UTC

Correlated Moves
News

RBC Capital maintains its Sector Perform rating on PTC Therapeutics and lowers its price target to $75, contributing to the stock's decline.

2026. okt. 6. 20:07 UTC

PTC Therapeutics Inc's shares are trading roughly flat, retracing from earlier gains and remaining below the 20-day moving average amid a routine biotechnology sector performance.

2026. szept. 28. 20:01 UTC

PTC Therapeutics Inc. is higher in Monday's trading session, continuing gains since Friday's close, despite an earlier pullback from a session high.

2026. szept. 25. 20:01 UTC

PTC Therapeutics Inc is advancing as the broader market gains, despite earlier pulling back from a session high amid rising Treasury yields and weak consumer sentiment.

2026. szept. 24. 20:07 UTC

PTC Therapeutics Inc. shares fell, closing below the 20-day moving average and near the lower end of its one-month range after midday fluctuations.

2026. szept. 23. 20:02 UTC

Correlated Moves

PTC Therapeutics Inc shares fell sharply amid a broader downturn in the biotechnology sector, influenced by significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

2026. szept. 18. 20:02 UTC

PTC Therapeutics Inc shares fell sharply, reversing a trend of higher daily closes seen in recent sessions, despite no specific news impacting the company.

2026. szept. 16. 19:06 UTC

News

PTC Therapeutics gained after Leerink Partners initiated coverage with an "outperform" rating and a $98.00 price target, while Jefferies and Citigroup upgraded their ratings.

2026. szept. 14. 20:08 UTC

News

Leerink has initiated coverage on PTC Therapeutics with an Outperform rating and a $98.00 price target, supporting a higher trading session since Friday's close.

2026. szept. 11. 19:56 UTC

Social Media

PTC Therapeutics Inc shares are lower today amid discussions from an investor event and plans for a Biologics License Application for a Fabry disease treatment.

2026. szept. 10. 23:41 UTC

PTC Therapeutics Inc shares are higher in after-market trading, gradually increasing since Thursday's close, despite remaining below their 20-day moving average.

2026. szept. 8. 20:07 UTC

Correlated Moves

Shares lower amid decline in iShares Biotechnology ETF.

2026. szept. 2. 20:08 UTC

PTC Therapeutics Inc. is gaining today, supported by a broader advance in biotechnology stocks, despite a pullback earlier in the session.

2026. aug. 31. 19:46 UTC

PTC Therapeutics shares are lower today, continuing a recent decline amid broader market unease following hawkish comments from Federal Reserve Chair Kevin Warsh.

2026. aug. 28. 23:36 UTC

PTC Therapeutics Inc shares are higher in after-market hours, recovering from an earlier dip. No specific news was identified to explain the movement.

2026. aug. 27. 20:07 UTC

PTC Therapeutics shares are lower today, continuing a decline since Wednesday's close, despite positive labor market data. No specific news was identified.

Társak összehasonlítása

Árváltozás

PTC Therapeutics Inc Előrejelzés

Célár

By TipRanks

44.99% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 100 USD  44.99%

Magas 137 USD

Alacsony 62 USD

12 Wall Street elemző 12 hónapos célárain alapulva a(z)PTC Therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

12 ratings

10

Vétel

2

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat